{"denoms":[{"counts":[{"groupId":"BG000","value":"28"}],"units":"Participants"}],"groups":[{"description":"NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity.\n\nSURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD). Patients who undergo EPP will then undergo radiation therapy.\n\nMAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity.","id":"BG000","title":"Treatment (Chemotherapy, Surgery +/- RT, Maintenance)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"31.5","upperLimit":"77.3","value":"68.1"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}],"title":"No"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown"}],"title":"Hispanic"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Extrapleural Pneumonectomy (EPP)"},{"measurements":[{"groupId":"BG000","value":"24"}],"title":"Pleurectomy/Decortication (PD)"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Surgery","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"1"}]}],"description":"Performance Status uses the Zubrod Scale as follows:\n\n0 - Fully active, able to carry on all pre-disease performance w/o restriction\n\n1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work","paramType":"COUNT_OF_PARTICIPANTS","title":"Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}],"title":"<6%"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"5-<10%"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Pending"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Weight Loss Past 6 Months","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}],"title":"Measurable"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Not Assessable"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Baseline Disease Status mRECIST","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Measurable"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Non-Measurable"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Baseline Disease Status RECIST","unitOfMeasure":"Participants"}]}